JENA, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten public offering of 8,250,000 ordinary shares of the Company at a public offering price of $2.00 per ordinary share and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 6,750,000 of the Company’s ordinary shares. The purcha ...

JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the pricing of its underwritten public offering of 8,250,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 6,750,000 of the Company’s ordinary shares. The purchase price of e ...

JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX) (the "Company"), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has commenced an underwritten public offering of ordinary shares of the Company, and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase the Company's ordinary shares. The purchase price of each pre-funded warrant will equal the price per share at which ordinary ...

Company Overview - InflaRx is a biopharmaceutical company specializing in anti-inflammatory therapeutics by targeting the complement system, particularly focusing on the C5a and C5aR pathways [2] - The company's lead product candidate, vilobelimab, is a first-in-class anti-C5a monoclonal antibody delivered intravenously, showing disease-modifying clinical activity and tolerability in multiple studies [2] - InflaRx is also developing INF904, an orally administered small molecule inhibitor of the C5a receptor [2] - Founded in 2007, the company has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA [2] - InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc (USA) are wholly owned subsidiaries of InflaRx NV [3] Upcoming Events - InflaRx will participate in the Guggenheim SMID Cap Biotech Conference, scheduled for February 5-6, 2025, in New York, NY [1] Contact Information - Jan Medina, CFA, serves as Vice President and Head of Investor Relations at InflaRx NV [4] - MC Services AG handles media and investor relations for InflaRx, with contacts including Katja Arnold, Laurie Doyle, and Dr Regina Lutz [4]

InflaRx N.V. (IFRX) shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing authorization, under exceptional circumstances, for Gohibic (vilobelimab) to treat adult patients with acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2. The targeted patient population in the EU comprises individuals receiving systemic corticosteroids as standard-of-care therapy and undergoing invasive mechanical ventilation, with or without extracorporeal membrane oxygenation.Th ...

JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances for GOHIBIC® (vilobelimab) for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of standard of care and receivin ...

JENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in multiple events the week of January 13, 2025, in San Francisco, CA. This activity will take place during the week of the 43rd Annual J.P. Morgan Healthcare Conference. LifeSci Partners Corporate Access Event1-on-1 meetings on January 14 and 15, 2025 Biotech Showcase 2025Works ...

JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), investigating the Company's oral C5aR inhibitor, INF904. Camilla Chong, MD, Chief Medical Officer of InflaRx, commented: "We are pleased to have started our Phase 2a trial fo ...

InflaRx N.V. (IFRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.22%. A quarter ago, it was expected that this company would post a loss of $0.21 per share when it actually produced a loss of $0.26, delivering a surprise of -23.81%.Over the last four quarters, the company has surpassed ...

INFLARX N.V. FINANCIAL STATEMENTS – SEPTEMBER 30, 2024 InflaRx N.V. is a company limited by shares, incorporated and domiciled in Amsterdam, The Netherlands. Its registered office and principal place of business is in Germany, Jena, Winzerlaer Str. 2. | --- | --- | --- | |------------|------------------------------------------------------------------------------------------------------------------------------------------|-------| | Unaudited | condensed consolidated statements of operations and comprehensiv ...